# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Clara Barton (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI024-SYN
- Date: 2026-02-03
- Fictional facility: St. Posthumous Health Center
- Fictional author: Eleanor Whitcombe, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week sertraline tolerability and safety check; psychiatry consultation today. **S**

## History of present illness

Ms. Barton returns two weeks after starting sertraline 50 mg each morning for a recurrent depressive episode. She took the two weeks of medical leave and has not been to the office, though she admits to answering some messages from home. She had mild nausea and loose stools in the first week, which have settled; she has had no headache, restlessness, agitation, or bleeding. She has missed no doses. She still wakes at 3 or 4 in the morning but now sleeps four to five hours. Her energy and interest are still low, though she walked with a friend twice this week. She has had no suicidal thoughts since the first visit and keeps her safety plan in her bag. Her first cognitive behavioral therapy session is booked for this week. She saw Dr. Mendes of psychiatry this morning. **S**

| Element | Detail |
|---|---|
| Medication tolerance | Mild nausea and loose stools in week one, now settled; no agitation or restlessness |
| Adherence | No missed doses |
| Sleep | Four to five hours, with early waking |
| Work | On two weeks of medical leave; answering some messages from home |
| Safety | No suicidal thoughts since intake; safety plan carried |
| PHQ-9 | 16, down from 18 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | Early nausea and loose stools resolved; no bleeding |
| Neurological | Negative | No headache, tremor, or restlessness |
| Constitutional | Positive | Fatigue persists; appetite slightly better |
| Psychiatric | Positive | Low mood and interest, early waking; no suicidal thoughts, elevated mood, or racing thoughts |

4 systems reviewed. **S**

## Current medications

- Sertraline 50 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/72 mmHg; pulse 78 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 99% on room air; weight 49.6 kg; BMI 21.5 kg/m². All vital signs are synthetic.

PHQ-9: 16. All results are synthetic.

## Change since baseline

- PHQ-9: 18 at baseline, 16 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Small, neatly dressed, tired |
| Mental status | Alert and cooperative; speech soft and slow; mood "a little less heavy"; affect constricted; thought process linear; no suicidal ideation; no psychotic features; insight and judgment good |
| Neurological | No tremor |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Major depressive disorder, recurrent, moderate** (F33.1). PHQ-9 16, down from 18 after two weeks, which is expected this early. Sertraline is well tolerated. Psychiatry confirms a recurrent major depressive episode, with no bipolar, psychotic, or PTSD features. Suicide risk is low, with no ideation since intake and protective factors unchanged. **S**
   - Continue sertraline 50 mg; review in four weeks, at six weeks of treatment, and increase to 100 mg if the PHQ-9 has fallen by less than 50 percent, as Dr. Mendes advised.
   - Start weekly cognitive behavioral therapy this week.
   - Collaborative safety plan reviewed and unchanged; 988 Suicide & Crisis Lifeline and the clinic number confirmed.
2. **Occupational burnout** (Z73.0). On medical leave but still answering messages, which keeps work in her head at night. **S**
   - A colleague will hold her inbox until her return; phased return from next week at no more than 25 hours a week, with no evening work.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 16, down from 18 at intake (11 percent) |
| Medication safety | SSRI tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Completed today | Early nausea and loose stools settled; no activation, agitation, or bleeding |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since intake; PHQ-9 item 9 scored 0. Protective factors unchanged. Safety plan reviewed: she carries her copy and has 988 and the clinic number saved |
| Medication safety | Adherence and adverse-effect review | Every visit during active treatment | Completed today | No missed doses; no headache, tremor, sexual side effects, or bleeding |
| Survey | Bipolar screen at the initial workup | Once, at the initial depression workup | Completed today | Psychiatric interview today found no past manic or hypomanic episode; no Mood Disorder Questionnaire score is recorded |
| Referral | Psychiatry consultation | For recurrent or complex episodes | Completed today | Seen today; diagnosis confirmed; combination treatment and titration plan agreed |
| Self-management | Psychotherapy, sleep, activity, and social contact | Every visit during active treatment | Completed today | CBT starts this week; two walks with a friend; sleep four to five hours |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Treated with an SSRI only |

## Goal progress

- Response (PHQ-9 down by at least 50 percent) by twelve weeks. In progress; target 2026-04-14. **S**
- Remission (PHQ-9 below 5) and continuation treatment for at least twelve months after remission. In progress; target 2026-06-16. **S**
- Sleep at least six hours most nights. In progress; target 2026-04-14. **S**
- Phased return to work at no more than 45 hours a week, with no field deployment for at least six months. In progress; target 2026-06-16. **S**
- Time with friends or her faith community at least twice a week. In progress; target 2026-06-16. **S**

## Guideline basis

- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Depression review in four weeks, six weeks after starting sertraline. **S**
- Next scheduled visit 2026-03-03: six-week depression treatment review. **S**
